The means by which antidepressants perform their function of making new brain cells is now understood. This it is believed will now help drug researchers develop more efficient ways to fight depression with developed medications.
It had been show by way of previous studies being carried out that the tricyclics a type of antidepressant along with the serotonin reuptake inhibitors do in fact generate new brain cells, but it was unknown up to now how this was achieved.
Key Protein
The new findings used Pfizer’s Zoloft and other antidepressants as their study matter. Researchers at Kings College London’s Institute of Psychiatry determined that this was done through a process involving glucocorticoid receptor (GR) which it is known is one of the key proteins used in the response to stress.
It was found that it is only with GR that new brain cells can be built.
Study Leader’s Words
Christoph Anacker, who is a doctorate student at the IoP and led the study, said,””Having identified the glucocorticoid receptor as a key player in making new brain cells, we will now be able to use this novel stem cell system to model psychiatric illnesses in the laboratory, test new compounds and develop much more effective, targeted antidepressant drugs.”
Global Benefit
That is the result, but what will be the real knock on benefit. Given that depression is so common, and believed to be suffered by more than 120 million individuals worldwide, it is no surprise to note how it is one of the world’s leading causes of disability. The reality is that only a quarter of these sufferers have any access to a means of treatment.
It has been shown in recent studies that there is a reduction in the process of ‘neurogenesis’ in depressed patients – This ‘neurogenesis’ is the process of developing new brain cells. This lack of being able to build new cells it is believed by researchers is why low mood and impaired memory occur in depressed persons.
Stem Cells
His team used stem cells in their work (human hippocampal) what are known as the source of new cells in the brain to show the effects play out of antidepressants, but this time on brain cells in the lab Petri dish.
The cells were treated with Zoloft which is similar in effect to Eli Lilly’s Prozac and other drugs like Paxil, these are all the SSRI class of drugs. The findings from the experiments however hold true for a different class of drugs also (serotonin and norepinephrine reuptake inhibitors (SNRIs) drugs like Pfizer’s Effexor and Eli Lilly’s Cymbalta.
Clinically Relevant Model
In a statement regarding the findings of the study Anacker said, “For the first time in a clinically relevant model, we were able to show that antidepressants produce more stem cells, and also accelerate their development into adult brain cells.”
The findings showed that the glucocorticoid receptor is positively essential; it needs to be in place for the growth to occur. This protein is then activated by the antidepressants converting immature stem cells into the needed adult brain cells.
Target
It is evident that it will not come overnight that new antidepressants will emerge as a result of the findings, but according to those involved with the study, it will take up to five years from now for new drugs to get to the point of patient testing. The scientists conclude that whilst they do now have some tools to probe the glucocorticoid receptor, there is not yet a drug that can do it effectively. It does however give the drug companies a target to reach.

Break Negative Thought Patterns To Combat Depression
According to recent research, the key to helping people overcome moderate to severe depression is to break those negative thought patterns. What we’re talking about here is Cognitive Therapy, which focuses more on changing how you think about things as opposed to changing how you behave.
The study, which was carried out by Daniel Strunk from Ohio State University, Melissa Brotman of the National Institute of Mental Health and Robert DeRubeis of the University of Pennsylvania, found that behaviour changing techniques had little effect on depression symptoms whereas breaking negative thought patterns did.
The study involved 60 patients who had been diagnosed with major depression. Each of the participants saw one of six cognitive therapists in a series of sessions and all of the participants agreed to their sessions with therapists being recorded on video.
The tapes of these recordings were then studied by trained raters who identified whether cognitive techniques or behavioural techniques were being used by the therapists. The patients were also asked to complete a depression questionnaire after each session.
On analysing the data the researchers noticed that depression symptoms improved significantly when the therapist used cognitive techniques.
“There has been a lot of attention recently on behavioural approaches to treating severe depression, and that may lead some people to suspect that cognitive techniques are not important for more severely depressed patients,” said Daniel Strunk, co-author of the study and assistant professor of psychology at Ohio State University.
“But our results suggest that it was the cognitive strategies that actually helped patients improve the most during the first critical weeks of cognitive-behavioural therapy.”
The research also revealed that patients who got more involved with the therapy process showed greater improvement.
“If you’re a patient and willing to fully commit to the therapy process, our data suggest you will see more benefit,” Strunk said.
The research is being continued at Ohio State’s Depression Treatment and Research Clinic and the researchers are hoping to shed more light on cognitive therapy and how it can help combat depression.
“We’re trying to understand if cognitive therapy leads people to a profound change in their basic self view, or if it teaches them a set of skills that they have to continually practice over time,” said Strunk.
The results have been published in the online version of the journal Behaviour Research and Therapy.